These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Local administration of cytostatic drug 4-hydroperoxy-cyclophosphamide (4-HPCY) facilitates cell-mediated immune reactions.
    Author: Boerrigter GH, Scheper RJ.
    Journal: Clin Exp Immunol; 1984 Oct; 58(1):161-6. PubMed ID: 6478648.
    Abstract:
    4-Hydroperoxy-cyclophosphamide (4-HPCY) is a cyclophosphamide (CY) derivative that, unlike CY, does not need liver conversion for its action. This new drug has been recently described to preferentially eliminate suppressor B and T lymphocytes in vitro in both mice and man. Using an in vivo contact sensitivity model in the guinea-pig, we introduced 4-HPCY into antigenically stimulated lymph nodes by local intradermal injection following sensitization. Strong potentiation of contact sensitization was achieved by local administration of doses higher than 50 micrograms 4-HPCY daily on 4 days subsequent to sensitization. Contact hypersensitivity was found to be enhanced for at least 6 weeks. In addition it could be demonstrated that local administration of 4-HPCY not only enhanced the development of delayed hypersensitivity in normal animals, but also facilitated the reversal of previously induced immunological tolerance. The applicability of this new strategy for potentiation of effector T cell function, especially with respect to the treatment of malignancies, is stressed.
    [Abstract] [Full Text] [Related] [New Search]